fbpx

News

Lundbeckfonden Ventures News

Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V. Progresses Acromegaly programme towards clinic. SynCo_Bio_Release_9_5_2011_(2).pdf
Funds to be used to complete two Phase II programmes
Nexstim, a medical device company, raises over EUR 11 million in new equity financing. Helsinki, Finland – January 26, 2011 – Nexstim Oy, a medical device company commercializing noninvasive brain diagnostic and therapy technologies, today announced that it has closed on additional equity financing of approximately EUR 11.4 million. The investment round was led by...
Russell G. Greig Appointed as Chairman of SyntaxinOxford, UK, 6th January 2011: Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announced Dr Russell G. Greig, Ph. D., has been appointed as Chairman with immediate effect. In joining Syntaxin, Dr. Greig brings with him over 30 years experience in the pharmaceutical industry,...
DBV Technologies closes $25.5 (?19,4) million Series ‘C’ financing round including new investors InnoBio, Lundbeckfond Ventures, Shire plc, and ALTO Invest; as well as existing investors Sofinnova Partners and ALK AbelloProceeds will be used, for the most part, to further continue the clinical development of VIASKIN® Peanut, the world’s first epicutaneous skin patch for desensitization...
Lundbeckfond Ventures is LFÍ Life Science Investments new name
1 66 67 68 69

Lundbeckfonden Ventures

News

Acacia – Issue of Equity on Exercise of Options/Vesting of Performance Share Awards
20. January 2021
Acacia Pharma wins BEL Small Company of the Year for the second consecutive year
20. January 2021
LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies for Rare and Non-Rare Monogenic Diseases
7. January 2021